https://www.statcounter.com/counter/counter.js
Home » Archives by category » Clinical Trial News (Page 4)
Calliditas initiates NEFIGARD trial to study Nefecon in Berger’s disease

Nefecon phase 3 trial : Calliditas Therapeutics has initiated a phase 3 clinical trial called NEFIGARD to evaluate its lead candidate Nefecon for the treatment of IgA nephropathy (IgAN), which is also known as Berger’s disease. Phase 3 NEFIGARD trial of Nefecon The Swedish pharma company has enrolled the first patient for the late-stage NEFIGARD […]

Continue reading …
Nordic Nanovector initiates Betalutin rituximab combo trial in 2L FL

Nordic Nanovector has announced the dosing of the first patient in a phase 1b clinical trial called Archer-1 for evaluating the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche cancer drug rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). Rituximab is a CD20-targeting monoclonal antibody that is given as a […]

Continue reading …
Mereo BioPharma begins BPS-804 mid-stage trial in osteogenesis imperfecta

British specialty biopharma company Mereo BioPharma Group has wrapped up enrollment of patients for a phase 2b clinical trial that will evaluate its human monoclonal antibody BPS-804 (Setrusumab) as a potential treatment option for osteogenesis imperfecta (OI), better known as the brittle bone disease. Osteogenesis imperfecta is a rare, chronic genetic disorder that makes bones […]

Continue reading …
Nordic Nanovector initiates mid-stage trial of Betalutin in 3L Follicular Lymphoma in US

Nordic Nanovector has opened its first clinical site in the US at Long Beach in California for the PARADIGME trial to evaluate its tumor-seeking anti-CD37 antibody Betalutin (lilotomab) in third-line (3L) follicular lymphoma. With the opening of the US clinical trial site, the Norwegian biopharma company has initiated the global randomized phase 2b trial of […]

Continue reading …
TWi Biotechnology initiates AC-203 phase 2 trial for Epidermolysis Bullosa

TWi Biotechnology, a Taiwanese biotech company, has announced the enrollment of the first patient in a phase 2 trial evaluating AC-203 for the treatment of inherited Epidermolysis Bullosa (EB). The phase 2 trial of AC-203 is a double-blind, intra-individual comparison, proof-of-concept clinical trial and will feature patients as young as two years of age. The […]

Continue reading …
BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer patients whose condition relapsed after platinum-based chemotherapy treatment. Opdivo could not significantly improve overall survival in the patients in comparison to current standard of care chemotherapy of topotecan or amrubicin […]

Continue reading …
MaaT Pharma doses first patient in HERACLES phase 2 trial of MaaT013

MaaT Pharma,a French oncology company, said that it has dosed the first patient in the HERACLES phase 2 trial of MaaT013, a microbiome restoration candidate, in patients with steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD). aGvHD is considered to be one of the major causes of death after an allogeneic stem cell transplant because of attack of the transplanted […]

Continue reading …
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and diagnostic discovery company’s COM701 in advanced solid tumors. COM701 is being investigated by Compugen as an anti-PVRIG antibody while the cancer drug Opdivo is a […]

Continue reading …
GNI Group to stop patient enrolment in F351 phase 2 liver fibrosis trial

Japanese biotech company GNI Group will end enrolment of new patients for a phase 2 liver fibrosis trial of its drug candidate F351 in China following the recommendation of an independent data monitoring committee based on the positive efficacy results achieved till date. So far, 175 out of the originally targeted 240 patients have been […]

Continue reading …
Five Prime, Zai Lab initiate phase 3 trial of bemarituzumab chemo combo

Five Prime Therapeutics and Zai Lab have dosed the first patient in a phase 3 study of bemarituzumab (FPA144) in combination with chemotherapy in patients having advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The late-stage trial named as FIGHT features advanced gastric cancer or gastroesophageal junction cancer patients who were not subjected to […]

Continue reading …